NEW YORK (AP) — Bristol-Myers Squibb Co. and Sanofi SA are restructuring their longtime partnership selling popular heart medications that now have widespread competition from generic versions — and plunging sales.
The two drugmakers made tens of billions of dollars over the last decade or so selling Plavix, a blood thinner that was long the world's second-best-selling drug. The companies also shared revenue from blood pressure drug Avapro and a related drug called Avalide that also includes a water pill.
The three medicines all got generic competition in the U.S. this spring. They already had generic rivals in other countries.
The new agreement would return to Sanofi all rights to sell the drugs in nearly all countries. Bristol-Myers would get some royalties from those sales and will continue to sell Plavix in the U.S.
Stumbling to War With Russia?
Decisions, decisions! Climate change has Charlie Daniels in a bit of a pickle
Trump denies mocking disabled reporter, demands apology
Donald Trump Mocks A Disabled New York Times Reporter | RedState
Dr. Mark Skousen - When Will the Market Doomsayers and Permabears Be Right?
Importing Terrorism and Other American Values | Human Events
Top 5 "Go To" Rifle Essentials - Bearing Arms - Video